Business Context and Reporting Period
This Form 8-K filing by Genelux Corp (GNLX) reports executive leadership changes effective January 29, 2025. The company is an emerging growth company incorporated in Delaware, with principal executive offices in Westlake Village, California.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and separation terms.
- Outgoing CFO Severance: Lourie Zak is eligible for a cash payment of approximately $180,000 (six months' base salary) paid in biweekly installments through August 29, 2025.
- Outgoing CFO Equity: Vested stock options remain exercisable for 12 months after the advisory period ends.
- Outgoing CFO Benefits: Includes up to 12 months of COBRA health insurance and eligibility for the 2024 annual bonus.
- Incoming CFO Compensation: Matt Pulisic receives a base salary of $410,000 annually with a target discretionary bonus of up to 40%.
- Incoming CFO Equity: Granted an option to purchase 275,000 shares at an exercise price of $3.95 per share, vesting over four years.
Material Changes
The primary material change is the departure of Lourie Zak as Chief Financial Officer and the appointment of Matt Pulisic to the role.
- Departure: Lourie Zak resigned effective January 29, 2025. She will serve as a non-employee advisor until August 29, 2025.
- Appointment: Matt Pulisic was appointed CFO effective January 30, 2025. He previously served as Vice President of Finance at Arrowhead Pharmaceuticals, Inc.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. It details specific risks and contingencies related to executive employment agreements:
- Severance Conditions: Ms. Zak's severance is conditioned on her not revoking the separation agreement within 21 days. Mr. Pulisic's severance benefits require signing a release of claims within 60 days of termination.
- Change in Control: Mr. Pulisic's unvested options accelerate to 100% vesting in the event of a change in control. His severance increases to 12 months of base salary plus full target bonus if terminated during the "Change in Control Period."
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price of the 275,000 stock options granted to Matt Pulisic.
- Confirm the total cash outflow for Lourie Zak's separation package, including the 2024 bonus eligibility.
- Review the full text of the Separation Agreement (Exhibit 10.1) for any non-compete or non-solicit clauses.
- Monitor the upcoming Form 10-Q for the quarter ending March 31, 2025, for the full text of the Pulisic Employment Agreement.